Clinical Trial

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Researchers are looking for new ways to treat locally advanced non-small cell lung cancer (NSCLC) that is unresected and has a gene mutation called KRAS G12C. Researchers want to learn if calderasib (MK-1084) can be given with durvalumab, an immunotherapy, to treat NSCLC after chemotherapy and radiation therapy. The goal of this trial is to learn if participants who receive calderasib and durvalumab live longer without the cancer growing or spreading compared to participants who receive placebo and durvalumab.
Protocol Amendment History 6 changes
notable Trial sites expanded: 35 -> 50 locations 2026-07-29
notable Trial sites expanded: 25 -> 33 locations 2026-07-11
notable Trial sites expanded: 16 -> 25 locations 2026-07-08
notable Trial sites expanded: 5 -> 16 locations 2026-06-27
critical Recruitment opened 2026-06-04
notable Trial sites expanded: 0 -> 5 locations 2026-06-04
Trial Details
NCT Number NCT07554339
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Non-small Cell Lung Cancer
Enrollment 310 participants
Start Date 2026-06-18
Primary Completion 2032-12-15 (estimated)
Study Completion 2037-08-17 (estimated)
Updated on ClinicalTrials.gov 2026-08-07